Xolair (Omalizumab) Patent Expiration, LOE Window & CMS Spending

Xolair (Omalizumab) by Roche / Genentech: Biologic BLA (Purple Book Regime), 0 AB generics, $686.3M 2024 CMS Part D & Medicaid spend, and 21 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRoche / Genentech
FDA Application & PathwayB103976 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$686.3M
2024 Medicare Part D Spend$313.1M
2024 Medicaid Spend$373.1M
Reported Wholesale Price Change (CA SB 17)21 WAC filings (max 20.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.